Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1986 Feb;23(2):230–234. doi: 10.1128/jcm.23.2.230-234.1986

Analysis of epidemiologic markers of nosocomial Serratia marcescens isolates with special reference to the Grimont biotyping system.

J Sifuentes-Osornio, G M Ruiz-Palacios, D H Gröschel
PMCID: PMC268618  PMID: 3517048

Abstract

Seventy-one strains of Serratia marcescens obtained from hospitalized patients of the Instituto Nacional de la Nutricion in Mexico City and two Virginia hospitals (University of Virginia Medical Center and Norfolk General Hospital) were analyzed to find markers useful for the epidemiologic investigation of outbreaks with this organism. Biotyping with commercial microwell systems (API 20# system [Analytab Products, Plainview, N.Y.] and DMS Rapid NFT [DMS Laboratories, Inc., Flemington, N.J.]) was not useful. Biotyping with the system designed by Grimont (assimilation tests, pigment production, and the ability to reduce tetrathionate broth) was helpful to characterize all strains. Of the 37 Mexican strains, 36 belonged to biogroup A 5/8 and 32 were biotype A8b. The 34 strains from the Virginia hospitals were distributed among six different biogroups and 12 biotypes. Significant differences in antimicrobial susceptibility (50% MIC, microgram/ml) between Mexican and Virginia strains were seen with carbenicillin (256 versus 8), piperacillin (64 versus 4), amikacin (16 versus 2), gentamicin (2 versus 0.5), and tobramycin (16 versus 2). Some Mexican strains showed variability in the susceptibility to amikacin because they were low producers of 6'-N-acetyltransferase type I. The Mexican strains seemed to come from a hospital with cross-infection problems because most were isolated from urine, were multiresistant, and more nonpigmented; in contrast, the strains isolated at University of Virginia Medical Center represent the experience of a hospital with scattered S. marcescens infections. The Grimont biotyping scheme is a useful epidemiologic tool for the clinical microbiologist.

Full text

PDF
230

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambrosio R. E., Van Wyk A. J., De Klerk H. C. Antibiotic-resistant Serratia marcescens infection in a hospital. S Afr Med J. 1979 Apr 7;55(15):584–587. [PubMed] [Google Scholar]
  2. Arroyo J. C., Milligan W. L., Postic B., Northey J., Parker E., Bryan C. S. Clinical, epidemiologic and microbiologic features of a persistent outbreak of amikacin-resistant Serratia marcescens. Infect Control. 1981 Sep-Oct;2(5):367–372. doi: 10.1017/s0195941700055508. [DOI] [PubMed] [Google Scholar]
  3. Brown A., Davis L., Yee R. B., Postic B. Endemic Serratia marcescens in the Veterans Administration Hospital in Pittsburgh, Pa., 1971--1976. Health Lab Sci. 1978 Jul;15(3):159–167. [PubMed] [Google Scholar]
  4. Chakravarti A., Mandal A., Sharma K. B. An outbreak due to multiple drug resistant Serratia marcescens in a children's hospital. Indian J Med Res. 1981 Aug;74:196–201. [PubMed] [Google Scholar]
  5. Coleman D., Falkiner F. R., Carr M. E., Dowd G., Dougan G., Keane C. T. Simultaneous outbreaks of infection due to Serratia marcescens in a general hospital. J Hosp Infect. 1984 Sep;5(3):270–282. doi: 10.1016/0195-6701(84)90076-8. [DOI] [PubMed] [Google Scholar]
  6. Farmer J. J., 3rd, Davis B. R., Hickman F. W., Presley D. B., Bodey G. P., Negut M., Bobo R. A. Detection of Serratia outbreaks in hospital. Lancet. 1976 Aug 28;2(7983):455–459. doi: 10.1016/s0140-6736(76)92539-3. [DOI] [PubMed] [Google Scholar]
  7. Grimont P. A., Grimont F. Biotyping of Serratia marcescens and its use in epidemiological studies. J Clin Microbiol. 1978 Jul;8(1):73–83. doi: 10.1128/jcm.8.1.73-83.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Grimont P. A., Grimont F., Le Minor S., Davis B., Pigache F. Compatible results obtained from biotyping and serotyping in Serratia marcescens. J Clin Microbiol. 1979 Oct;10(4):425–432. doi: 10.1128/jcm.10.4.425-432.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lewis D. A., Hawkey P. M., WattsJA, Speller D. C., Primavesi R. J., Fleming P. J., Pitt T. L. Infection with netilmicin resistant Serratia marcescens in a special care baby unit. Br Med J (Clin Res Ed) 1983 Dec 3;287(6406):1701–1705. doi: 10.1136/bmj.287.6406.1701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Montanaro D., Grasso G. M., Annino I., De Ruggiero N., Scarcella A., Schioppa F. Epidemiological and bacteriological investigation of Serratia marcescens epidemic in a nursery and in a neonatal intensive care unit. J Hyg (Lond) 1984 Aug;93(1):67–78. doi: 10.1017/s0022172400060940. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Okuda T., Endo N., Osada Y., Zen-Yoji H. Outbreak of nosocomial urinary tract infections caused by Serratia marcescens. J Clin Microbiol. 1984 Oct;20(4):691–695. doi: 10.1128/jcm.20.4.691-695.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Piguet J. D. Oxydation et fermentation de l'arabinose, du mélibiose et du xylose par Serratia. Ann Microbiol (Paris) 1978 Aug-Sep;129B(2):167–173. [PubMed] [Google Scholar]
  13. Pitt T. L., Erdman Y. J., Bucher C. The epidemiological type identification of Serratia marcescens from outbreaks of infection in hospitals. J Hyg (Lond) 1980 Apr;84(2):269–283. doi: 10.1017/s0022172400026772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Pitt T. L. State of the art: typing of Serratia marcescens. J Hosp Infect. 1982 Mar;3(1):9–14. doi: 10.1016/0195-6701(82)90026-3. [DOI] [PubMed] [Google Scholar]
  15. Platt D. J., Sommerville J. S. Serratia species isolated from patients in a general hospital. J Hosp Infect. 1981 Dec;2(4):341–348. doi: 10.1016/0195-6701(81)90066-9. [DOI] [PubMed] [Google Scholar]
  16. Roemisch E., Kocka F. E. Comparison of methods for differentiating among Serratia marcescens isolated from clinical specimens. Am J Clin Pathol. 1976 Jul;66(1):96–100. doi: 10.1093/ajcp/66.1.96. [DOI] [PubMed] [Google Scholar]
  17. Sanders C. C., Sanders W. E., Jr Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev Infect Dis. 1983 Jul-Aug;5(4):639–648. doi: 10.1093/clinids/5.4.639. [DOI] [PubMed] [Google Scholar]
  18. Schaberg D. R., Alford R. H., Anderson R., Farmer J. J., 3rd, Melly M. A., Schaffner W. An outbreak of nosocomial infection due to multiply resistant Serratia marcescens: evidence of interhospital spread. J Infect Dis. 1976 Aug;134(2):181–188. doi: 10.1093/infdis/134.2.181. [DOI] [PubMed] [Google Scholar]
  19. Smith P. J., Brookfield D. S., Shaw D. A., Gray J. An outbreak of Serratia marcescens infections in a neonatal unit. Lancet. 1984 Jan 21;1(8369):151–153. doi: 10.1016/s0140-6736(84)90074-6. [DOI] [PubMed] [Google Scholar]
  20. Traub W. H. Antibiotic susceptibility of clinical isolates of Serratia marcescens compared with sensitivity to group A (phage tail) bacteriocins. Chemotherapy. 1978;24(5):301–313. doi: 10.1159/000237797. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES